SABCS23 Day 2 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the second day’s highlights from X/Twitter.
”SABCS23 Day 2 Highlights Community Oncology:
HR+
1. Update CM7FL + KN756
2. MONARCH3
3. HER2CLIMB02 (Her2+)
4. Role of Anthracyclines
5. OLAnzaPiNE (all solid tumors)
1. CM7FL and KN756 PeriOp IO/NeoAdj chemo -> cut -> Adj IO in early HR+ Breast Cancer
– pCR mainly w/ N+ and low ER (how much does adj IO add in HR+ and TNBC? Adj IO w/ Atezolizumab in TNBC a study),
– If correct, use NeoAdj IO/Chemo then PARPi/CDK 4/6i in Adj? Sherene Loi.
For the more information click here.
2. MONARCH3 8 year follow-up: Abemaciclib + AI vs AI in HR+ mBC 1L:
– Ribo > Abema > Palbo?For the more information click here.
– Brain Mets mPFS 7.8 vs 5.7 mos (HR: 0.64),
– now, potentially 3 options in 2L: TDxD, Tucatinib + TDM1, and Tucatinib + Cape + Trastuzumab.For the more information click here.
4. Use of Anthracyclines: Prior to SABCS, we discussed this article by Paolo Tarantino– Hal Burstein Borges, and Piccart,
– Use should be limited to TNBC and “considered” in small subset of Hr+.
For the more information click here.
5. OLAnzaPiNE: low vs standard dose olanzapine in all Solid tumors using highly emetogenic chemo.
– Low dose (2.5mg) is non-inferior to standard dose (10mg),
– Improved AE (such as daytime somnolence).”
Source: Oncology Brothers/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023